Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
MALT1
REST API REST API
Homo sapiens
MALT1 is differentially expressed in 345 experiments: 156 organism parts: blood, thymus, ... (154 more);, 246 disease states: normal, prostate carcinoma, ... (244 more);, 110 cell types 521 cell lines 41 compound treatments and 79 other conditions.
Synonyms MLT
Orthologs MALT1 (Gallus gallus)   Malt1 (Mus musculus)   MALT1 (Danio rerio)   MALT1 (Bos taurus)   Malt1 (Rattus norvegicus)   malt1 (Xenopus laevis)   MALT1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, protein binding, cytoplasm, innate immune response, protein complex, protein ubiquitination, nuclear export, peptidase activity, positive regulation of protein ubiquitination, anti-apoptosis, signal transducer activity, protein oligomerization, defense response, cysteine-type endopeptidase activity, protein self-association, nucleus, ubiquitin-protein ligase activity, perinuclear region of cytoplasm, proteolysis, positive regulation of NF-kappaB transcription factor activity, response to fungus, regulation of apoptosis, protease binding, positive regulation of I-kappaB kinase/NF-kappaB cascade, T cell receptor signaling pathway, positive regulation of T cell activation, positive regulation of interleukin-2 production, positive regulation of T cell cytokine production, B cell activation, positive regulation of phosphorylation, T cell proliferation, B-1 B cell differentiation, response to molecule of bacterial origin, kinase activator activity, activation of NF-kappaB-inducing kinase activity, regulation of T cell receptor signaling pathway, CBM complex
InterPro Term Ig_sub, Pept_C14_ICE_p20, Immunoglobulin, Ig-like, Pept_C14_cat, Ig_sub2, Ig_I-set
UniProt Accession Q9UDY8
Search EB-eye ENSG00000172175
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-MEXP-433, E-GEOD-3526, ... (29 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-18005, E-GEOD-2450, E-MTAB-62, E-GEOD-21750, ... (51 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-20081, E-GEOD-19639, E-GEOD-3529, E-GEOD-5823
HL-60
1
3
E-GEOD-24147, E-GEOD-5258, E-MTAB-37, E-GEOD-96
primary culture
2
E-GEOD-2450, E-GEOD-1657
BT-474
2
E-GEOD-5823, E-GEOD-3529
DU145
2
E-GEOD-17482, E-GEOD-20089
HCC38
2
E-MTAB-62, E-MTAB-37
515 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, E-GEOD-2822, ... (56 experiments)

Factor Value U/D Experiments
CD19+ B cells (neg. sel.)
2
E-AFMX-5, E-TABM-145
CD56+ NK cells
2
E-AFMX-5, E-TABM-145
cardiac myocyte
1
2
E-AFMX-5, E-TABM-145, E-MTAB-25
CD8+ T cell
1
2
E-GEOD-6740, E-TABM-145, E-AFMX-5
primary blood vessel endothelial cell
1
E-MEXP-66
human foreskin fibroblast
1
E-GEOD-18265
104 more value(s).


Disease state

studied in E-GEOD-3307, E-MEXP-1121, E-GEOD-1577, E-MTAB-62, E-MTAB-680, ... (69 experiments)

Factor Value U/D Experiments
prostate carcinoma
1
4
E-MTAB-62, E-GEOD-7307, E-GEOD-96, E-GEOD-5377, E-MEXP-2034 ... (5 experiments)
control
3
E-GEOD-21912, E-GEOD-8121, E-GEOD-20602
leiomyosarcoma
2
E-MEXP-1922, E-MTAB-37
neuroblastoma
2
E-MTAB-37, E-MTAB-62
chronic myelogenous leukemia
2
E-MTAB-37, E-MTAB-62
progeria syndrome
1
E-MTAB-62
240 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5741, E-TABM-782, E-GEOD-3720, E-MEXP-1958, ... (29 experiments)

Factor Value U/D Experiments
R547
1
E-GEOD-15389
phenol
1
E-GEOD-6907
R1881
1
E-GEOD-12438
mercury dichloride
1
E-GEOD-6907
docosahexaenoic acid
1
E-MEXP-1014
ethanol
1
E-MEXP-1014
35 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
32
2
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-860, E-MEXP-1251, ... (12 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, ... (9 experiments)

Dfs follow up
studied in E-GEOD-22541

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, E-GEOD-2509, E-GEOD-22148, ... (9 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, ... (8 experiments)

Genotype
studied in E-GEOD-1923, E-GEOD-22056, E-GEOD-3494, E-GEOD-21750, E-MEXP-421, ... (10 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-MEXP-2657, E-GEOD-22278, E-GEOD-10315, E-TABM-440, ... (13 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-1956, E-MEXP-2069, ... (42 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-MEXP-561

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-GEOD-2004

Phenotype
studied in E-GEOD-22229, E-GEOD-19703, E-GEOD-1493, E-GEOD-21750, E-GEOD-1657, ... (7 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19246, ... (6 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10896

RNAi
studied in E-MEXP-1509, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-GEOD-17400, E-GEOD-18995 ... (5 experiments)

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-1643, E-GEOD-7307

Stimulation
studied in E-GEOD-20114

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-43, E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-21909, E-GEOD-19246, E-GEOD-13818, ... (7 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-1561

Processing time: 0.293 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM